UCB/Celltech Exec Chairman Will Be UCB Pharma’s Doliveux
This article was originally published in The Pink Sheet Daily
Current UCB Group Executive Committee Chairman Georges Jacobs will be replaced by UCB Pharma CEO Roch Doliveux effective Jan. 1. Jacobs will chair the board of directors.
You may also be interested in...
Celltech's TNF inhibitor CDP-870 is crown jewel of $2.7 bil. acquisition; a BLA filing is expected in 2007. UCB CEO Roch Doliveux will continue to serve as chief executive, while Celltech CEO Goran Ando will become deputy CEO.
Senior VP-Global Clinical & Pharmaceutical Development Elliott Sigal is acting president of Bristol-Myers Squibb’s research institute following the death of James Palmer.
The four-pronged plan will address “bio-burden,” manufacturing techniques, quality systems and execution, CEO Pien says. Chiron has met twice with U.K. authorities and hopes to realize similar progress with FDA soon.